News

Our collaborative research with Keio University, exploring the anti-fibrotic properties of hepatic progenitor cells via extracellular vesicles, has been selected as a FY2024 AMED* project for its practical application in addressing hepatitis and related diseases.

Mar 28 2024

We believe that this recognition signifies its potential practical application in addressing hepatitis and related ailments.

Click here for details . *Japan Agency for Medical Research and Development

【5th consecutive year】Takahiro Ochiya, our founder and CSO, was selected as a Highly Cited Researcher for the fifth consecutive year by Clarivate Web of Science.

Nov 17 2023

Professor Takahiro Ochiya has been selected as a highly cited paper author by Clarivate Web of Science for five consecutive years.

Click here for details .

Article in the evening edition of the Yomiuri Newspaper on June 1, 2023, regarding the cell therapy research being conducted by Nagasaki University with the support of AMED, using our CLiP patents

June 1 2023

The liver of a miniature pig is similar to the liver of a human. Researchers first made a model NASH infected liver, of which they cultured a sample in vitro with a low molecular compound to make a liver progenitor(“CLiP”) cell, and the CLiP cells were then returned to the pig. This resulted in the fibrotic livers dissolving and being restored to normal healthy livers. This positive result bodes well for Evia’s IP, because it suggests that this form of therapy may be available for patients whose only option was a liver transplant.

Click here for details. (Article only available in Japanese)

Dr. Ochiya received the Distinguished Achievement Award from the Japanese Society for Regenerative Medicine at the 22nd Annual Meeting of the Japanese Society for Regenerative Medicine

March 24 2023

Dr. Ochiya was granted the award for his research on EVs secreted by liver progenitor cells created with our proprietary reprogramming patent "Method for producing hepatic stem / progenitor cells from mature hepatocytes using low molecular weight compounds", which was first time announced in 2016.

The award was also given for his ongoing research at EVIA and in academia on liver therapeutics using these EVs, and for his contributions to the development of regenerative medicine research in Japan.

Click here for details.

The Scientific Committee of PMDA released a report on therapeutic formulations using extracellular vesicles (EV) containing exosomes.

Jan 24 2023

The Scientific Committee of PMDA* released a “Report on Therapeutic Preparations Using Extracellular Vesicle (EV) Containing Exosomes”. This report summarizes the quality and safety considerations of therapeutic formulations based on EV research, and serves as a reference for the development of EV therapeutics.

Click here for details. (Article only available in Japanese)
* PMDA: Pharmaceuticals and Medical Devices Agency of Japan

【4th consecutive year】Takahiro Ochiya, our founder and CSO, was selected as a Highly Cited Researcher for the fourth consecutive year by Web of Science.

Nov 18 2022

Professor Takahiro Ochiya has been selected as a highly cited paper author by Web of Science for four consecutive years.